Table 2.

Hazard ratios of features associated with recurrence-free survival.

Select Characteristics		n = 71 n (%)a	Unadjusted HR (95% CI)**c	Adjusted HR (95% CI)***
LVSI	No	49 (69)	Ref	Ref
	Yes	22 (31)	1.7 (0.4–7.5)	1.9 (0.4–8.5)
p53 mutationb	No	16 (23)	Ref	*
	Yes	16 (23)	0.8 (0.3–2.1)
Assessed ≥4 pelvic lymph nodes	No	20 (28)	Ref	*
	Yes	51 (72)	1.7 (0.2–14)
Assessed ≥3 Para-aortic lymph nodes	No	55 (77)	Ref	*
	Yes	16 (23)	0.4 (0.05–3.2)
Received adjuvant chemotherapy	No	28 (39)	Ref	*
	Yes	43 (61)	2.6 (0.3–21.8)
Received 6 cycles of adjuvant chemotherapy	No chemotherapy	28 (40)	Ref	*
	Chemotherapy (<6 cycles)	10 (14)	8.5 (0.9–82.5)
	Chemotherapy (6 cycles)	32 (45)	1.6 (0.2–15.1)
Received 6 cycles of adjuvant chemotherapy	No chemotherapy or < 6 cycles	38 (54)	Ref	Ref
	6 cycles of chemotherapy	32 (45)	0.5 (0.1–2.4)	0.4 (0.1–2.0)
>2 co-morbidities	No	47 (66)	Ref	Ref
	Yes	24 (34)	0.4 (0.05–3.4)	0.3 (0.05–2.7)
Diabetes	No	56 (79)	Ref	*
	Yes	14 (20)	2.5 (0.5–13.0)
Hypertension	No	32 (46)	Ref	*
	Yes	38 (54)	0.3 (0.1–1.7)
Pulmonary disease	No	60 (85)	Ref	*
	Yes	10 (14)	2.5 (0.5–12.8)

^*Not a significant predictor after controlling for other variables.

^**Univariable model on age, T stage, peritoneal cytology, history of renal disease do not converge well or do not yield statistically significant associations.

^***Multivariable model includes percent of clear cell component as covariate.

^aPercentages may not add up to 100% due to missing data.

^bMissing data or mutation status not assessed in a subset of cases.

^cAdditionally, age, race, BMI, menopausal status, tobacco use, history of hormone replacement therapy use, history of oral contraceptive use, omental sampling, sentinel lymph node assessment, FIGO stage, type of chemotherapy, receipt of adjuvant radiation therapy, and type of radiation therapy were tested but did not yield statistically significant HRs in univariable models and did not statistically significantly impact adjusted HRs in multivariable models.